Our Pricing

Wegovy Safety: Real UK Clinical Trial Results

Wondering is Wegovy safe UK clinical trial results can confirm? As a UK-registered pharmacy with thousands of patients prescribed semaglutide, we've seen firsthand how understanding the clinical evidence helps patients make informed decisions. Wegovy (semaglutide 2.4mg) has been rigorously tested in multiple international trials and approved by the MHRA for weight management in the UK.

What Clinical Trials Tell Us About Wegovy Safety

The STEP (Semaglutide Treatment Effect in People with obesity) programme represents the largest clinical trial dataset for Wegovy, involving over 4,500 participants across five major studies [1]. These randomised, double-blind trials assessed safety and efficacy over 68 weeks, providing robust evidence that informed MHRA licensing decisions in the UK.

In the pivotal STEP 1 trial, 86.4% of participants completed the full 68-week study period, demonstrating good tolerability [1]. The most common adverse events were gastrointestinal — nausea (44% vs 17% placebo), diarrhoea (30% vs 16%), and vomiting (24% vs 6%) — with most cases classified as mild to moderate and occurring during dose escalation phases [1].

Serious adverse events occurred in 9.8% of semaglutide participants versus 6.4% on placebo, though most were unrelated to treatment [1]. Importantly, the trial found no increased risk of pancreatitis, and gallbladder-related events occurred in 2.6% of participants, consistent with expected rates during significant weight loss [2].

Real-World Weight Loss Results from UK Clinical Data

Clinical trials consistently demonstrate substantial weight reduction with Wegovy. In STEP 1, participants achieved an average 14.9% body weight reduction over 68 weeks compared to 2.4% with placebo [1]. More than two-thirds (69%) of Wegovy participants lost at least 10% of their starting weight, and nearly one-third (32%) achieved reductions exceeding 20% [1].

The STEP 2 trial specifically examined adults with type 2 diabetes, a population commonly seen in UK primary care. These participants averaged 9.6% weight loss with semaglutide 2.4mg versus 3.4% on placebo, alongside improvements in HbA1c levels [3]. This dual benefit makes Wegovy particularly relevant for UK patients managing both obesity and metabolic conditions.

Long-term data from the STEP 4 trial assessed weight maintenance after initial loss. Participants who continued Wegovy maintained their weight reduction, whilst those switched to placebo regained 6.9% of body weight over 48 weeks [4]. This evidence supports the understanding that semaglutide works as a chronic weight management medication requiring ongoing treatment.

Cardiovascular Safety Profile

The SELECT cardiovascular outcomes trial enrolled over 17,600 adults with established cardiovascular disease, demonstrating that semaglutide 2.4mg reduced major adverse cardiovascular events by 20% compared to placebo [5]. This landmark finding led to MHRA approval for cardiovascular risk reduction in adults with obesity, positioning Wegovy beyond simple weight management into preventative cardiology.

Common Side Effects and How to Manage Them

Gastrointestinal side effects are the most frequently reported with Wegovy, affecting approximately 44-74% of patients depending on the specific symptom [1]. These typically emerge during dose escalation and diminish over time as your body adapts to the medication. At Cured Pharmacy, our clinical team advises patients to eat smaller, more frequent meals and avoid high-fat foods during the initial weeks.

Nausea is usually most pronounced in the first 4-8 weeks and tends to resolve as you reach maintenance dosing [1]. If symptoms persist, your UK prescriber may slow the titration schedule or recommend antiemetic strategies. Staying well-hydrated and avoiding lying down immediately after eating can also help minimise discomfort.

Less common side effects include injection site reactions (5.3%), fatigue (11%), and constipation (24%) [1]. Serious adverse events are rare but include potential gallbladder complications in approximately 2.6% of patients, typically associated with rapid weight loss rather than the medication itself [2]. Your prescriber will assess your gallbladder history during consultation.

When to Contact Your Prescriber

Seek immediate medical attention if you experience severe abdominal pain, persistent vomiting, signs of pancreatitis (upper abdominal pain radiating to the back), or symptoms of thyroid tumours (neck lump, difficulty swallowing, persistent hoarseness) [2]. Whilst these events are rare, early recognition is essential. Our UK clinical team at Cured Pharmacy remains available throughout your treatment for safety monitoring and dose adjustments.

Who Should Not Use Wegovy: UK Contraindications

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), as preclinical studies identified thyroid C-cell tumours in rodents [2]. Whilst human relevance remains uncertain, MHRA guidance mandates this precaution across all GLP-1 receptor agonists.

The medication is not licensed for use during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception throughout treatment [2]. If you're planning pregnancy, discontinue Wegovy at least 2 months before conception due to the medication's long half-life. Your UK prescriber will discuss family planning during your clinical assessment.

Patients with a history of severe gastrointestinal disease, including gastroparesis or inflammatory bowel disease, may not be suitable candidates due to Wegovy's effect on gastric emptying [2]. Similarly, those with active gallbladder disease, severe renal impairment (eGFR <30), or unstable diabetic retinopathy require careful evaluation before starting treatment.

Is Wegovy Safe UK Clinical Trial Results Compared to Alternatives

When comparing GLP-1 receptor agonists available in the UK, Wegovy demonstrates a safety profile consistent with the medication class whilst delivering superior weight loss outcomes. The STEP trials showed 14.9% average weight reduction versus 9.6% seen with liraglutide in the SCALE trials [1][6]. Both medications share similar gastrointestinal side effect profiles, though Wegovy's once-weekly dosing may improve adherence compared to daily injections.

Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, achieved 22.5% average weight loss in SURPASS-3 trials, exceeding semaglutide's results [7]. However, tirzepatide's dual mechanism also produces comparable gastrointestinal tolerability, with nausea reported in 33-36% of participants [7]. Your UK prescriber will consider individual tolerance, medical history, and treatment goals when recommending between these options.

Older weight management medications like orlistat carry different safety considerations — primarily gastrointestinal side effects related to fat malabsorption rather than nausea [8]. Naltrexone-bupropion combinations present neuropsychiatric monitoring requirements. The choice between these UK-licensed treatments depends on your cardiovascular risk profile, diabetes status, and previous medication responses, all assessed during your clinical consultation at Cured Pharmacy.

Long-Term Safety Monitoring

Ongoing pharmacovigilance through the MHRA's Yellow Card scheme continues to monitor Wegovy's real-world safety profile in UK populations. Current post-marketing data align with clinical trial findings, with no unexpected safety signals emerging [2]. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures all adverse events are appropriately reported and patients receive regular safety reviews throughout treatment.

Starting Wegovy Safely: What to Expect from UK Prescribers

All Wegovy prescriptions at Cured Pharmacy begin with a comprehensive clinical assessment by UK-registered prescribers. This evaluation reviews your BMI, weight-related comorbidities, previous weight loss attempts, medication history, and contraindications. The MHRA licenses Wegovy for adults with BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related condition such as hypertension, type 2 diabetes, or obstructive sleep apnoea [2].

Treatment follows a standardised dose escalation schedule designed to minimise gastrointestinal side effects: starting at 0.25mg weekly for 4 weeks, then increasing monthly through 0.5mg, 1mg, and 1.7mg before reaching the maintenance dose of 2.4mg [2]. This gradual titration allows your body to adapt to semaglutide's effects on gastric emptying and appetite regulation. Your prescriber may adjust this schedule based on your individual tolerability.

Wegovy is available at Cured Pharmacy from £79.00, with transparent pricing shown before your consultation. This includes your UK prescription, genuine MHRA-licensed medication, and discreet next-day delivery. Our clinical team provides ongoing support throughout your treatment, with regular check-ins to monitor progress, manage side effects, and adjust dosing as needed. All prescription medications require clinical assessment by a UK prescriber before dispensing.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK.
3. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
5. Lincoff, A. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
6. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
7. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
8. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.